HEALTH-RELATED QUALITY-OF-LIFE OUTCOMES 4-YEARS AFTER TREATMENT WITH VALOCTOCOGENE ROXAPARVOVEC FP Careta; B Madan; MC Ozelo; G Kenet; S Chou; S Pipe; A Leavitt; A Ruiz; E Dashiell-Aje; J Mahlangu;

BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1 MC Ozelo; J Mahlangu; B Madan; J Mason; F Peyvandi; AV Drygalski; G Yamaguti-Hayakawa; TM Robinson; SW Pipe; TT Gener-Eigh;

BLEEDING RATE, FVIII UTILIZATION, CORTICOSTEROID USE, QUALITY OF LIFE AND SAFETY 4-YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC IN A BRAZILIAN COHORT: RESULTS FROM GENER8-1 MC Ozelo; GGY Hayakawa; ANL Prezotti; MH Cerqueira; PR Villaça; C Lorenzatto; T Robinson;